These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 24266507)
1. Prognostic impact of monocyte count at presentation in mantle cell lymphoma. George A; Prince HM; Szer J; Wolf M; Januszewicz EH; Seymour JF; Ritchie DS Br J Haematol; 2014 Mar; 164(6):890-3. PubMed ID: 24266507 [No Abstract] [Full Text] [Related]
2. Prognostic impact of monocyte count at presentation in mantle cell lymphoma - response to George et al. von Hohenstaufen KA; Conconi A; de Campos CP; Zucca E Br J Haematol; 2014 Mar; 164(6):893-4. PubMed ID: 24251543 [No Abstract] [Full Text] [Related]
3. Absolute monocyte count at diagnosis and survival in mantle cell lymphoma. Porrata LF; Ristow K; Markovic SN Br J Haematol; 2013 Nov; 163(4):545-7. PubMed ID: 23961917 [No Abstract] [Full Text] [Related]
4. Prognostic impact of monocyte count at presentation in mantle cell lymphoma. von Hohenstaufen KA; Conconi A; de Campos CP; Franceschetti S; Bertoni F; Margiotta Casaluci G; Stathis A; Ghielmini M; Stussi G; Cavalli F; Gaidano G; Zucca E Br J Haematol; 2013 Aug; 162(4):465-73. PubMed ID: 23808798 [TBL] [Abstract][Full Text] [Related]
6. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience. Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847 [TBL] [Abstract][Full Text] [Related]
7. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ritchie DS; Seymour JF; Grigg AP; Roberts AW; Hoyt R; Thompson S; Szer J; Prince HM Ann Hematol; 2007 Feb; 86(2):101-5. PubMed ID: 17089127 [TBL] [Abstract][Full Text] [Related]
8. Outcome of mantle cell lymphoma patients treated at a single institution over the past decade. Hitz F; Diem S; Haile SR; Ess S; Cerny T; Mey U Hematol Oncol; 2014 Dec; 32(4):192-6. PubMed ID: 24338732 [TBL] [Abstract][Full Text] [Related]
9. Blastic mantle cell leukemia: an unusual presentation of blastic mantle cell lymphoma. Viswanatha DS; Foucar K; Berry BR; Gascoyne RD; Evans HL; Leith CP Mod Pathol; 2000 Jul; 13(7):825-33. PubMed ID: 10912944 [TBL] [Abstract][Full Text] [Related]
10. Autoimmune haemolytic anaemia in mantle cell lymphoma : an insidious complication associated with leukemic disease. Doni E; Carli G; Di Rocco A; Sassone M; Gandolfi S; Patti C; Falisi E; Salemi C; Visco C Hematol Oncol; 2017 Mar; 35(1):135-137. PubMed ID: 26078106 [No Abstract] [Full Text] [Related]
11. Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma. Markovic O; Popovic L; Marisavljevic D; Jovanovic D; Filipovic B; Stanisavljevic D; Matovina-Brko G; Hajder J; Matkovic T; Živkovic R; Stanisavljevic N; Todorović M; Petrovic D; Mihaljevic B Eur J Intern Med; 2014 Mar; 25(3):296-302. PubMed ID: 24565533 [TBL] [Abstract][Full Text] [Related]
13. Mantle cell lymphoma with lymphocyte aggregates in peripheral blood. Farrugia D; Grech M; Camilleri D Br J Haematol; 2019 Aug; 186(3):395. PubMed ID: 31124577 [No Abstract] [Full Text] [Related]
14. A Doctor Asks the Lab to Send Cyanide to the Intensive Care Unit. Moore LM; Ramanathan LV Clin Chem; 2019 Oct; 65(10):1335. PubMed ID: 31570417 [No Abstract] [Full Text] [Related]
15. Occam's Razor and the Diagnosis of Mantle Cell Lymphoma. Lui JK; Gillespie W; Gaudet R; Brettler DB Am J Med; 2015 Dec; 128(12):e25-6. PubMed ID: 26235247 [No Abstract] [Full Text] [Related]
16. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine. Inamdar KV; Romaguera JE; Drakos E; Knoblock RJ; Garcia M; Leventaki V; Medeiros LJ; Rassidakis GZ Cancer; 2009 Oct; 115(20):4727-36. PubMed ID: 19708031 [TBL] [Abstract][Full Text] [Related]
17. Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan. Chihara D; Asano N; Ohmachi K; Kinoshita T; Okamoto M; Maeda Y; Mizuno I; Matsue K; Uchida T; Nagai H; Nishikori M; Nakamura S; Ogura M; Suzuki R Br J Haematol; 2015 Sep; 170(5):657-68. PubMed ID: 25953436 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of peripheral blood absolute monocyte count and lymphocyte to monocyte ratio in anaplastic large cell lymphoma. Jia T; Zhang R; Zhu HY; Liang JH; Wang L; Wu W; Cao L; Li JY; Xu W Cancer Biomark; 2018; 22(4):807-813. PubMed ID: 29945349 [TBL] [Abstract][Full Text] [Related]
19. Motor-dominant polyneuropathy due to IgM monoclonal antibody against disialosyl gangliosides in a patient with mantle cell lymphoma. Mori A; Ueno Y; Kuroki T; Hoshino Y; Shimura H; Sekiguchi Y; Noguchi M; Hamada Y; Kusunoki S; Hattori N; Urabe T J Neurol Sci; 2014 Feb; 337(1-2):215-8. PubMed ID: 24315580 [TBL] [Abstract][Full Text] [Related]
20. Pertinence of the Sysmex XE-5000™ parameters: rule of slide review in a context of 'normal' lymphocyte count (defined from control and mantle cell lymphoma blood specimens). Chhuy J; Morel D; Goeddert G; Magaud JP; Felman P; Baseggio L Int J Lab Hematol; 2013 Oct; 35(5):510-6. PubMed ID: 23279807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]